Efficacy and safety of interleukin‐17 inhibitors in the treatment of chronic rheumatic diseases: A combined and updated meta‐analysis
出版年份 2021 全文链接
标题
Efficacy and safety of interleukin‐17 inhibitors in the treatment of chronic rheumatic diseases: A combined and updated meta‐analysis
作者
关键词
-
出版物
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2021-03-26
DOI
10.1111/jcpt.13416
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial
- (2020) Christopher T Ritchlin et al. LANCET
- Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study
- (2020) Désirée van der Heijde et al. ANNALS OF THE RHEUMATIC DISEASES
- Secukinumab improves signs and symptoms of non‐radiographic axial spondyloarthritis: primary results of a randomized controlled phase III study
- (2020) Atul Deodhar et al. Arthritis & Rheumatology
- Systemic effects of IL-17 in inflammatory arthritis
- (2019) Audrey Beringer et al. Nature Reviews Rheumatology
- Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial
- (2019) Atul Deodhar et al. LANCET
- Pathophysiology of axial spondyloarthritis: Consensus and controversies
- (2018) Anoek de Koning et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison
- (2018) Joy Feld et al. Nature Reviews Rheumatology
- The role of HLA-B*27 in spondyloarthritis
- (2018) Robert A. Colbert et al. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
- Beyond the TNF-α Inhibitors: New and Emerging Targeted Therapies for Patients with Axial Spondyloarthritis and their Relation to Pathophysiology
- (2018) Susanne Juhl Pedersen et al. DRUGS
- Effects of the IL-23–IL-17 pathway on bone in spondyloarthritis
- (2018) Ellen M. Gravallese et al. Nature Reviews Rheumatology
- Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
- (2018) Désirée van der Heijde et al. LANCET
- Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: 16 Week Results of a Phase 3 Randomized, Double-Blind, Placebo Controlled Trial in Patients with Prior Inadequate Response or Intolerance to Tumor Necrosis Factor
- (2018) Atul Deodhar et al. Arthritis & Rheumatology
- Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
- (2017) Peter Nash et al. LANCET
- Role of HLA-B27 in the pathogenesis of ankylosing spondylitis
- (2017) Bin Chen et al. Molecular Medicine Reports
- Psoriatic Arthritis
- (2017) Christopher T. Ritchlin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
- (2016) Jürgen Braun et al. ANNALS OF THE RHEUMATIC DISEASES
- Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
- (2016) Philip J Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Back pain and health status in patients with clinically diagnosed ankylosing spondylitis, psoriatic arthritis and other spondyloarthritis: a cross-sectional population-based study
- (2016) Ulf Lindström et al. BMC MUSCULOSKELETAL DISORDERS
- Targeting the interleukin-23/17 axis in axial spondyloarthritis
- (2016) Ananta Paine et al. CURRENT OPINION IN RHEUMATOLOGY
- HLA-B27
- (2015) Paul Bowness Annual Review of Immunology
- Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Iain B McInnes et al. LANCET
- Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
- (2015) Dominique Baeten et al. NEW ENGLAND JOURNAL OF MEDICINE
- Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
- (2015) Philip J. Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- HLA-B27 and psoriatic disease: a modern view of an old relationship
- (2015) Rubén Queiro et al. RHEUMATOLOGY
- American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
- (2015) Michael M. Ward et al. Arthritis & Rheumatology
- Update on Ankylosing Spondylitis: Current Concepts in Pathogenesis
- (2014) Judith A. Smith CURRENT ALLERGY AND ASTHMA REPORTS
- Development of Criteria to Distinguish Inflammatory from Noninflammatory Arthritis, Enthesitis, Dactylitis, and Spondylitis: A Report from the GRAPPA 2013 Annual Meeting
- (2014) P. J. Mease et al. JOURNAL OF RHEUMATOLOGY
- Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis
- (2014) Philip J. Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
- (2013) Iain B McInnes et al. ANNALS OF THE RHEUMATIC DISEASES
- HLA-B27 misfolding and ankylosing spondylitis
- (2013) Robert A. Colbert et al. MOLECULAR IMMUNOLOGY
- The link between HLA-B27 and SpA--new ideas on an old problem
- (2012) K. McHugh et al. RHEUMATOLOGY
- Differential Features Between Primary Ankylosing Spondylitis and Spondylitis Associated with Psoriasis and Inflammatory Bowel Disease
- (2011) R. PEREZ ALAMINO et al. JOURNAL OF RHEUMATOLOGY
- Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility
- (2011) David M Evans et al. NATURE GENETICS
- Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis
- (2010) Yang Mei et al. CLINICAL RHEUMATOLOGY
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started